A total of 100 serotypes of RV-A and RV-B were identified by 198711. years demonstrated that RV-A and RV-C illnesses induced nAb responses of similar duration. == Conclusions: == These results indicate that both RV-A and RV-C nAb responses have only modest cross-reactivity that LY 303511 is limited to genetically similar types. Contrary to our initial hypothesis, RV-C species may include even fewer cross-neutralizing types than RV-A, whereas the duration of nAb responses during childhood is similar between the two species. The modest heterotypic responses suggest that RV vaccines must have a broad representation of prevalent types. Keywords:Rhinovirus, neutralizing antibodies, duration, cross-neutralization, vaccine == 1. INTRODUCTION == Rhinovirus (RV) is the most common virus detected in acute respiratory illnesses. All three RV species (RV-A, RV-B, and RV-C) can cause upper respiratory illnesses (URIs); however, RV-A and RV-C are more likely to cause wheezing illnesses in preschool-aged children and in children and adults with asthma13. While no options are currently available to treat or prevent RV infection, new developments suggest that a polyvalent RV vaccine could be feasible4. Young children, especially those with a polymorphism (rs6967330) in the RV-C receptor geneCDHR3, represent a high-risk group that could benefit from a vaccine5. After natural infection, neutralizing antibody (nAb) responses to RV-A and RV-B develop in the serum and mucosal secretions of most infected persons and can persist in serum for at least one year68. High serum RV nAb titers protect against RV infection6,9,10. A total of 100 serotypes of RV-A and RV-B were identified by LY 303511 198711. More recently, the numbering system has been extended to 112 types12. Neutralization tests with RV reference rabbit and guinea pig sera showed limited cross-neutralization between serotypes of these two speciesin vitro. Of 90 tested RV serotypes, 50 were classified in 16 antigenic groups13. However, it is unknown whether these heterotypic nAb responses enable cross-protection against RV infectionsin vivo. Discovered in 2006, the RV-C species is classified into 57 types based on the sequence identity thresholds in the VP1 capsid gene14, but there is limited information about their serological relationships. Total IgG responses to synthetic RV-C peptides were measured in several prior studies15,16, and assays for detection of nAbs to RV-C have recently been developed17,18. We reported that nAbs to RV-C in children develop earlier and are 23 times more prevalent than nAbs to RV-A throughout childhood17. These findings suggest that RV-C infections can induce cross-neutralizing antibodies or antibody responses of longer duration than those elicited by RV-A. Identifying cross-neutralization patterns could inform the development of a polyvalent RV-C vaccine. Our previous study pooled diagnostic virology data from over 10,000 RV-positive clinical samples obtained from children in the United States, Finland, and Australia17. Many children in this pooled cohort contracted a series of illnesses caused by various RV-A and RV-C types. The main goal of this study was to analyze the chronological sequences of LY 303511 RV illnesses to infer potential patterns of cross-neutralization and to test whether RV-C infections are more likely to induce cross-neutralizing antibody responses compared with RV-A infections. We reasoned that if a specific order of infections with two RV types occurred less often than expected, this could indicate that the first virus induced a cross-neutralizing antibody response that reduced the risk of infection and illness with the second virus. To experimentally verify these findings, we immunized mice with specific RV-C types and then used those reference sera and banked human plasma specimens to test for cross-neutralizing antibody responses. Additionally, we tested plasma specimens obtained from the same birth cohort participants multiple times Rabbit Polyclonal to Collagen II throughout childhood to determine nAb persistence following natural LY 303511 RV-A and RV-C illnesses. == 2. MATERIALS AND METHODS == == 2.1. Statistical analysis of sequential patterns of RV infections == Viral diagnostic data19,20were pooled from 14 studies of respiratory health in children17to estimate the relative frequency of illnesses caused by specific RV types. Study designs included prospective birth or infant cohorts and asthma treatment studies that involved a broad range of ages and demographics. Data from 11 studies included serial sampling of nasal secretions for RV diagnostics across more than one illness, and the results.